Basilea Pharmaceutica - Executive interview – Basilea Pharmaceutica
Basilea Pharmaceutica is a Switzerland-based biopharmaceutical company established in 2000 as a spin-out from Roche with the divestment of its anti-infective portfolio. Basilea was listed on the SIX Swiss Stock Exchange in 2004 and is well funded through its key near-term milestones. Revenue growth will be driven from its two marketed anti-infectives: Cresemba (antifungal – for invasive mould infections) and Zevtera (antibiotic – for hospital infections), which are commercialised globally through partners such as Pfizer and Astellas. It has several oncology assets in clinical development, which represent the next pillar of growth, including derazantinib, a pan-FGFR kinase inhibitor, which is currently in a registrational Phase II study for bile duct cancer.In this video, CEO David Veitch introduces the company, its assets and sets out the key near-term milestones.
Basilea Pharmaceutica is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of bacterial infections, fungal infections, oncology and skin diseases. Co. focuses on antibiotics and antifungals as well as oncology and dermatology drugs. Co.'s portfolio spans from innovative early-stage through clinical late-stage drug candidates to a marketed product. In the context of its international commercialization organization, Co. has subsidiaries in Denmark, France, Germany, Italy, Spain and the United Kingdom.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.